TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12972485

Group type: EXPERIMENTAL
Intervention: Postinjection immobilisation in elastic wrist orthoses (n=58)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Normal postinjection activity (n=59)
Number of subjects: 117
Study: 11219162

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (100,000 IU)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Measles vaccine
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Poliomyelitis vaccine
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation and measles vaccine interaction
Number of subjects: 300
Study: 8808520

Group type: EXPERIMENTAL
Intervention: KCl (7 mEq in 200 mL of 0.9% NaCl)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: MgSO4 (10 mL 20% in 200 mL of 0.9% NaCl)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Procainamide (maximal dose, 10 mg/kg of body weight over a 5‐minute period)
Number of subjects: 12

Group type: COMPARATOR
Intervention: NaCl (0.9%, 200 mL)
Number of subjects: 12
Study: 1329220

Group type: EXPERIMENTAL
Intervention: Combination carboplatin/etoposide/vincristine (CEV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Etoposide/vincristine (control)
Number of subjects: 0
Study: 4057572

Group type: EXPERIMENTAL
Intervention: PAV therapy in stage IV cases
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PAV therapy in operable cases
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bestatin treatment in stage Ib and II cases
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PPSM treatment with prophylactic lymph node dissection
Number of subjects: 0

Group type: COMPARATOR
Intervention: PPSM treatment without prophylactic lymph node dissection
Number of subjects: 0
Study: 30366505

Group type: COMPARATOR
Intervention: Filtered Back Projection (FBP) with 120 kV and 300 mA (Group A)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Adaptive Iterative Dose Reduction 3D (AIDR3D) with 80 kV and auto mA (Group B)
Number of subjects: 90
Study: 29366667

Group type: EXPERIMENTAL
Intervention: Traditional approach (TA)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Perpendicular approach (PA)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Axillary approach (AA)
Number of subjects: 18
Study: 27162030

Group type: EXPERIMENTAL
Intervention: Pulmonary vein antrum isolation
Number of subjects: 513
Study: 24731889

Group type: EXPERIMENTAL
Intervention: Osteopathic sham therapy
Number of subjects: 206

Group type: COMPARATOR
Intervention: Routine pediatric care (Control)
Number of subjects: 206
Study: 22613238

Group type: EXPERIMENTAL
Intervention: Kinesio Taping
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham Taping
Number of subjects: 60
Study: 20853611

Group type: EXPERIMENTAL
Intervention: V1 - bortezomib 1.3 mg/m2 intravenously on days 1, 4, 8, and 11 of a 21-day cycle
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: V2 - bortezomib 1.3 mg/m2 intravenously on days 1, 4, 8, and 11, melphalan 20 mg orally on day 2 of a 28-day cycle
Number of subjects: 101
Study: 17204317

Group type: EXPERIMENTAL
Intervention: HFA‐BDP (400 microg/d)
Number of subjects: 58

Group type: COMPARATOR
Intervention: FP (500 microg/d)
Number of subjects: 58
Study: 15123761

Group type: EXPERIMENTAL
Intervention: High-intensity strength training (HI; n = 8)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Low-moderate intensity strength training (LI; n = 6)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Weight-free placebo-control training (PC; n = 8)
Number of subjects: 22
Study: 12165364

Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS)
Number of subjects: 17
Study: 9717679

Group type: EXPERIMENTAL
Intervention: Priorix lot 1
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Priorix lot 2
Number of subjects: 255

Group type: COMPARATOR
Intervention: M-M-R II
Number of subjects: 255
Study: 9306483

Group type: EXPERIMENTAL
Intervention: HIV-1 infected children
Number of subjects: 458

Group type: COMPARATOR
Intervention: Seroreverter infants
Number of subjects: 458

Group type: COMPARATOR
Intervention: Control infants
Number of subjects: 458

Group type: EXPERIMENTAL
Intervention: Chloroquine use
Number of subjects: 458
Study: 1959461

Group type: EXPERIMENTAL
Intervention: Prazosin (alpha-adrenergic blocker)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 7238141

Group type: EXPERIMENTAL
Intervention: Skill training
Number of subjects: 36

Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 36

Group type: COMPARATOR
Intervention: Nontreatment control
Number of subjects: 36
Study: 30777846

Group type: EXPERIMENTAL
Intervention: RAW Mindfulness Program (6 sessions)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: RAW Mindfulness Program (5 to 6 sessions completed)
Number of subjects: 143
Study: 28035659

Group type: EXPERIMENTAL
Intervention: Patch testing for food additives
Number of subjects: 24
Study: 23568405

Group type: EXPERIMENTAL
Intervention: Newsletter with comprehensive health risk information insert
Number of subjects: 0

Group type: COMPARATOR
Intervention: Newsletter with brief health risk information
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Discussion of breast cancer risk with physician
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Discussion of heart disease risk with physician
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Discussion of osteoporosis risk with physician
Number of subjects: 0
Study: 21187207

Group type: EXPERIMENTAL
Intervention: Foot and ankle strength measures (hallux plantar flexion strength)
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Ankle inversion-eversion range of motion
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Clinical measures of foot and ankle strength, range of motion, posture, and deformity
Number of subjects: 305
Study: 19920724

Group type: EXPERIMENTAL
Intervention: Low-frequency pulsed electromagnetic field (PEMF) therapy
Number of subjects: 56

Group type: COMPARATOR
Intervention: Sham therapy
Number of subjects: 56
Study: 17310933

Group type: EXPERIMENTAL
Intervention: Monosegmental balloon kyphoplasty
Number of subjects: 60

Group type: COMPARATOR
Intervention: Adjacent prophylactic balloon kyphoplasty
Number of subjects: 60
Study: 14603267

Group type: EXPERIMENTAL
Intervention: Ketamine 0.4 mg/kg
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Ketamine 0.8 mg/kg
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 54
Study: 11292931

Group type: EXPERIMENTAL
Intervention: Intermittent cold blood cardioplegia (Group 1)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Terminal warm cardioplegia and controlled reperfusion (Group 2)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (Group 3)
Number of subjects: 90
Study: 9034275

Group type: EXPERIMENTAL
Intervention: Prophylactic ranitidine treatment for 4 days
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group (no ranitidine treatment)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Surfactant treatment for infant respiratory distress syndrome
Number of subjects: 53
Study: 8498463

Group type: EXPERIMENTAL
Intervention: Choice of which of five ceramic objects to paint
Number of subjects: 22

Group type: COMPARATOR
Intervention: No choice of ceramic object to paint (control)
Number of subjects: 22
Study: 3538477

Group type: EXPERIMENTAL
Intervention: Aminophylline calculated without knowledge of admission serum theophylline concentration (Group A)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Aminophylline calculated with knowledge of admission serum theophylline concentration (Group B)
Number of subjects: 50
Study: 30340715

Group type: EXPERIMENTAL
Intervention: Online fundus photograph program
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 46
Study: 27033352

Group type: EXPERIMENTAL
Intervention: IQ·SPECT with half the standard injected activity (462.5-550 MBq)
Number of subjects: 93

Group type: COMPARATOR
Intervention: LEHR collimators with full injected activity (925-1100 MBq)
Number of subjects: 93
Study: 24885949

Group type: EXPERIMENTAL
Intervention: Hombre Seguro sexual risk reduction intervention
Number of subjects: 400

Group type: COMPARATOR
Intervention: Time-attention didactic control condition
Number of subjects: 400
Study: 22230963

Group type: EXPERIMENTAL
Intervention: FOCUS Shear (F)
Number of subjects: 182

Group type: COMPARATOR
Intervention: LigaSure LF1212 (L)
Number of subjects: 182
Study: 20378080

Group type: EXPERIMENTAL
Intervention: Mipomersen 100 mg/week and higher
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Mipomersen 200 mg/week
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Mipomersen
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Mipomersen 200 mg/week (13-week cohort)
Number of subjects: 74
Study: 19142279

Group type: EXPERIMENTAL
Intervention: Nurse led model of care for chronic conditions
Number of subjects: 0
Study: 15791113

Group type: EXPERIMENTAL
Intervention: Intravenous acetaminophen (1 g)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Propacetamol (2 g)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study: 12422025

Group type: EXPERIMENTAL
Intervention: Physical Exercise (PE)
Number of subjects: 860

Group type: EXPERIMENTAL
Intervention: Stress Management Training (SMT)
Number of subjects: 860

Group type: EXPERIMENTAL
Intervention: Integrated Health Programme (IHP)
Number of subjects: 860

Group type: COMPARATOR
Intervention: Control
Number of subjects: 860
Study: 10091913

Group type: EXPERIMENTAL
Intervention: Three‐period crossover design
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Model without carryover effects
Number of subjects: 0

Group type: COMPARATOR
Intervention: Latin square design
Number of subjects: 0
Study: 8748429

Group type: EXPERIMENTAL
Intervention: 200 mg of nefazodone (NEF) twice daily
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 2 mg of lorazepam (LOR) twice daily
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Combination of 2 mg of LOR and 200 mg of NEF (LOR+NEF) twice daily
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo (PLA) twice daily
Number of subjects: 48
Study: 1681162

Group type: EXPERIMENTAL
Intervention: sumatriptan 100 mg
Number of subjects: 61

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 61
Study: 6626477

Group type: EXPERIMENTAL
Intervention: Exposure to 100 ppm of toluene for 6.5 hours
Number of subjects: 75

Group type: COMPARATOR
Intervention: Exposure to 0 ppm of toluene for 6.5 hours
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Chronic exposure to toluene vapour at concentrations of about 100 ppm for 17 years
Number of subjects: 75
Study: 31472160

Group type: EXPERIMENTAL
Intervention: Diabetic retinopathy eyes
Number of subjects: 80

Group type: COMPARATOR
Intervention: Normal control subjects
Number of subjects: 80
Study: 31238161

Group type: EXPERIMENTAL
Intervention: Abatacept therapy (weekly or every other week administration)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Abatacept therapy
Number of subjects: 22

Group type: COMPARATOR
Intervention: Abatacept therapy (every 4 weeks)
Number of subjects: 22
Study: 29025270

Group type: EXPERIMENTAL
Intervention: Tailored colorectal cancer screening decision aid including a values clarification exercise and individualized decision-making worksheet
Number of subjects: 424

Group type: COMPARATOR
Intervention: Attention control group receiving an educational pamphlet on safe driving behaviors
Number of subjects: 424
Study: 27307704

Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate 3-monthly injections (PP-3M)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 25157899

Group type: EXPERIMENTAL
Intervention: Closed-ended comprehension assessment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Open-ended comprehension assessment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perceived ease of comprehension
Number of subjects: 0
Study: 23069273

Group type: EXPERIMENTAL
Intervention: Vagally mediated heart rate variability (HRV) measured using HF-power (ms(2))
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Panic-related distress
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Duration of panic disorder (PD)
Number of subjects: 36
Study: 19648684

Group type: EXPERIMENTAL
Intervention: Orthosis combined with walker
Number of subjects: 126

Group type: COMPARATOR
Intervention: Improved hip frog cast fixation
Number of subjects: 126
Study: 17560664

Group type: EXPERIMENTAL
Intervention: Acetaminophen + diphenhydramine + pseudoephedrine (Group-1)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Acetaminophen only (Group-2)
Number of subjects: 148
Study: 15120369

Group type: EXPERIMENTAL
Intervention: Division of all short gastric vessels
Number of subjects: 99

Group type: COMPARATOR
Intervention: Intact short gastric vessels
Number of subjects: 99
Study: 11597378

Group type: EXPERIMENTAL
Intervention: Oral pilocarpine (OP)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 9855155

Group type: EXPERIMENTAL
Intervention: Topical 0.25% verapamil (single drop)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Topical 0.25% verapamil (2-week administration)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (single drop)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (2-week administration)
Number of subjects: 20
Study: 8028387

Group type: EXPERIMENTAL
Intervention: Epsilon-aminocaproic acid
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 2925973

Group type: EXPERIMENTAL
Intervention: Behavioral marital therapy (BMT)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Insight-oriented marital therapy (IOMT)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Treatment-on-demand (TOD) waiting-list control group
Number of subjects: 79
Study: 31654154

Group type: EXPERIMENTAL
Intervention: Effective photobiomodulation session applied at the main respiratory muscles using a cluster with 69 LEDs (35 red at 630±10 nm, 10 mW, 0.2 cm²; 34 near-infrared at 830±20 nm, 10 mW, 0.2 cm²)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sham photobiomodulation session (no light emitted)
Number of subjects: 12
Study: 31206975

Group type: EXPERIMENTAL
Intervention: NIV ± O2
Number of subjects: 29

Group type: COMPARATOR
Intervention: LFO2
Number of subjects: 29
Study: 29073592

Group type: EXPERIMENTAL
Intervention: Dronabinol
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study: 25963445

Group type: EXPERIMENTAL
Intervention: CEPIDEA School-Based Program
Number of subjects: 291

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 291
Study: 23764394

Group type: EXPERIMENTAL
Intervention: Stretching exercises (10-minute duration after working hours for 3 months)
Number of subjects: 134
Study: 21527660

Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 337

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 337
Study: 18321745

Group type: EXPERIMENTAL
Intervention: Topical application of 0.01% raspberry ketone (RK)
Number of subjects: 10
Study: 16236532

Group type: EXPERIMENTAL
Intervention: Local anaesthetic flush (bupivacaine 0.25% + adrenaline)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Saline control flush
Number of subjects: 100
Study: 14522625

Group type: EXPERIMENTAL
Intervention: 2% licorice topical gel
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 1% licorice topical gel
Number of subjects: 60

Group type: COMPARATOR
Intervention: Base gel (control)
Number of subjects: 60
Study: 10903010

Group type: EXPERIMENTAL
Intervention: Pencil-point needle (Pencan, B. Braun)
Number of subjects: 313

Group type: COMPARATOR
Intervention: Quincke needle (Spinocan, B. Braun)
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Meta-analysis of pencil-point needle
Number of subjects: 313
Study: 8981141

Group type: EXPERIMENTAL
Intervention: Laser zona opening (PALM UV Laser microbeam) applied on embryos from group A (216 laser-treated and 223 not treated)
Number of subjects: 407

Group type: EXPERIMENTAL
Intervention: Laser zona opening (PALM UV Laser microbeam) applied on embryos from group B (218 laser-treated embryos only)
Number of subjects: 407

Group type: COMPARATOR
Intervention: Control group (98 patients, embryos not laser treated)
Number of subjects: 407
Study: 1599063

Group type: EXPERIMENTAL
Intervention: Transdermal hyoscine (Scopoderm TTS CIBA)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study: 3910832

Group type: EXPERIMENTAL
Intervention: Computer based education (CBE)
Number of subjects: 0
Study: 31438863

Group type: EXPERIMENTAL
Intervention: Circuit Resistance Training (CRT) 3 home sessions/week for 10 weeks
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Ad-libitum plant-based Mediterranean diet (limited consumption of eggs, dairy, and fish; avoidance of red meat and poultry)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg/day
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: CRT added to empagliflozin and diet arms for an additional 10 weeks
Number of subjects: 120
Study: 30517579

Group type: EXPERIMENTAL
Intervention: Educational and motivational video intervention for controlling liquid intake.
Number of subjects: 192

Group type: COMPARATOR
Intervention: Control Group (no specific intervention mentioned).
Number of subjects: 192
Study: 27799756

Group type: EXPERIMENTAL
Intervention: Ectoin® inhalation solution
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24612637

Group type: EXPERIMENTAL
Intervention: Quality Improvement Collaboratives (QICs) participation
Number of subjects: 32
Study: 22340923

Group type: EXPERIMENTAL
Intervention: Patient education program
Number of subjects: 528

Group type: COMPARATOR
Intervention: Historical cohort (control)
Number of subjects: 528
Study: 20035240

Group type: EXPERIMENTAL
Intervention: Histone deacetylase inhibitor vorinostat
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17038533

Group type: EXPERIMENTAL
Intervention: RIC-HSCT
Number of subjects: 99
Study: 15823183

Group type: EXPERIMENTAL
Intervention: Fluticasone administered twice daily
Number of subjects: 1517

Group type: COMPARATOR
Intervention: Fluticasone administered once daily
Number of subjects: 1517
Study: 11956267

Group type: EXPERIMENTAL
Intervention: Adjuvant therapy with Melacine vaccine
Number of subjects: 689

Group type: COMPARATOR
Intervention: Observation (control group)
Number of subjects: 689

Group type: EXPERIMENTAL
Intervention: Adjuvant therapy with Melacine vaccine among HLA-A2-positive and/or HLA-C3-positive patients
Number of subjects: 689

Group type: COMPARATOR
Intervention: Observation (control group) among HLA-A2-positive and/or HLA-C3-positive patients
Number of subjects: 689
Study: 9652612

Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy (LC)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Open cholecystectomy (OC)
Number of subjects: 63
Study: 7647348

Group type: EXPERIMENTAL
Intervention: Smoking cessation instruction (approximately 2 minutes)
Number of subjects: 426
Study: 2748714

Group type: EXPERIMENTAL
Intervention: triazolam 0.5 mg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: lormetazepam 2 mg
Number of subjects: 120

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 120
Study: 322821

Group type: EXPERIMENTAL
Intervention: 1 g amoxycillin plus 1 g probenecid
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: 3 g amoxycillin plus 1 g probenecid
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Sensitivity of Neisseria gonorrhoeae to amoxycillin
Number of subjects: 104
Study: 31254678

Group type: EXPERIMENTAL
Intervention: Time2bHealthy online program for parents
Number of subjects: 0

Group type: COMPARATOR
Intervention: Emailed links to information from an evidence-based parenting website
Number of subjects: 0
Study: 28778185

Group type: EXPERIMENTAL
Intervention: Complete resection (95-100%)
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Gross total resection (90-95%)
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Incomplete resection (50-90%)
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Biopsy (<50%)
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Image Defined Risk Factors (IDRF)
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: MYCN (non-amplified)
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: MYCN (amplified)
Number of subjects: 179
Study: 26999837

Group type: EXPERIMENTAL
Intervention: Systemic steroid + intratympanic steroid as supplementary treatment (group A)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Initial intratympanic steroid (group B)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Intratympanic steroid as supplementary treatment (12 patients in group A)
Number of subjects: 68
Study: 24280743

Group type: EXPERIMENTAL
Intervention: Metformin (850 mg bid)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 21679264

Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg/day)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 19500127

Group type: EXPERIMENTAL
Intervention: Mohs micrographic surgery (MMS) with 2-mm margins
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard surgery with 4-mm margins
Number of subjects: 30
Study: 16679259

Group type: EXPERIMENTAL
Intervention: Dobutamine 2D
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Dobutamine TDI
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Dobutamine SRI
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Tl SPECT
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Combined SRI indexes with Tl SPECT
Number of subjects: 41
Study: 15151263

Group type: EXPERIMENTAL
Intervention: rhGH therapy (0.25 IU/kg subcutaneously 3x/week after each dialysis session)
Number of subjects: 19
Study: 11125344

Group type: EXPERIMENTAL
Intervention: New cleanser (soaked dentures)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Water (soaked dentures)
Number of subjects: 35
Study: 9294877

Group type: EXPERIMENTAL
Intervention: Creatine supplementation (18.75 g creatine monohydrate daily for 5 days prior to and 2.25 g creatine daily during testing)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (5 g of calcium chloride daily for 5 days prior to the first set of work bouts)
Number of subjects: 18